Cloprednol is a synthetic glucocorticoid that has been investigated for use in the treatment of asthma. A31775,A31776
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Denosumab | The risk or severity of adverse effects can be increased when Denosumab is combined with Cloprednol. |
| Etanercept | The risk or severity of adverse effects can be increased when Etanercept is combined with Cloprednol. |
| Peginterferon alfa-2a | The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Cloprednol. |
| Interferon alfa-n1 | The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Cloprednol. |
| Interferon alfa-n3 | The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Cloprednol. |
| Peginterferon alfa-2b | The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Cloprednol. |
| Anakinra | The risk or severity of adverse effects can be increased when Anakinra is combined with Cloprednol. |
| Interferon gamma-1b | The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Cloprednol. |
| Interferon alfa-2a | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Cloprednol. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Cloprednol. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Cloprednol. |
| Pegaspargase | The serum concentration of Cloprednol can be increased when it is combined with Pegaspargase. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Cloprednol. |
| Interferon beta-1b | The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Cloprednol. |
| Interferon alfacon-1 | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Cloprednol. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Cloprednol. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Cloprednol. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Cloprednol. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Cloprednol. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Cloprednol. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Cloprednol. |
| Alefacept | The risk or severity of adverse effects can be increased when Alefacept is combined with Cloprednol. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Cloprednol. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Cloprednol. |
| Interferon alfa-2b | The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Cloprednol. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Cloprednol. |
| Phenylalanine | The risk or severity of adverse effects can be increased when Phenylalanine is combined with Cloprednol. |
| Cladribine | Cloprednol may increase the immunosuppressive activities of Cladribine. |
| Carmustine | The risk or severity of adverse effects can be increased when Carmustine is combined with Cloprednol. |
| Amsacrine | The risk or severity of adverse effects can be increased when Amsacrine is combined with Cloprednol. |
| Bleomycin | The risk or severity of adverse effects can be increased when Bleomycin is combined with Cloprednol. |
| Chlorambucil | The risk or severity of adverse effects can be increased when Chlorambucil is combined with Cloprednol. |
| Raltitrexed | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Cloprednol. |
| Mitomycin | The risk or severity of adverse effects can be increased when Mitomycin is combined with Cloprednol. |
| Bexarotene | The risk or severity of adverse effects can be increased when Bexarotene is combined with Cloprednol. |
| Floxuridine | The risk or severity of adverse effects can be increased when Floxuridine is combined with Cloprednol. |
| Tioguanine | The risk or severity of adverse effects can be increased when Tioguanine is combined with Cloprednol. |
| Dexrazoxane | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Cloprednol. |
| Streptozocin | The risk or severity of adverse effects can be increased when Streptozocin is combined with Cloprednol. |
| Trifluridine | The risk or severity of adverse effects can be increased when Trifluridine is combined with Cloprednol. |
| Gemcitabine | The risk or severity of adverse effects can be increased when Gemcitabine is combined with Cloprednol. |
| Epirubicin | The risk or severity of adverse effects can be increased when Epirubicin is combined with Cloprednol. |
| Chloramphenicol | The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Cloprednol. |
| Lenalidomide | The risk or severity of adverse effects can be increased when Lenalidomide is combined with Cloprednol. |
| Altretamine | The risk or severity of adverse effects can be increased when Altretamine is combined with Cloprednol. |
| Zidovudine | The risk or severity of adverse effects can be increased when Zidovudine is combined with Cloprednol. |
| Oxaliplatin | The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Cloprednol. |
| Fluorouracil | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Cloprednol. |
| Propylthiouracil | The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Cloprednol. |
| Pentostatin | The risk or severity of adverse effects can be increased when Pentostatin is combined with Cloprednol. |
| Linezolid | The risk or severity of adverse effects can be increased when Linezolid is combined with Cloprednol. |
| Clofarabine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Cloprednol. |
| Pemetrexed | The risk or severity of adverse effects can be increased when Pemetrexed is combined with Cloprednol. |
| Mycophenolate mofetil | The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Cloprednol. |
| Tretinoin | The metabolism of Tretinoin can be increased when combined with Cloprednol. |
| Dacarbazine | The risk or severity of adverse effects can be increased when Dacarbazine is combined with Cloprednol. |
| Temozolomide | The risk or severity of adverse effects can be increased when Temozolomide is combined with Cloprednol. |
| Penicillamine | The risk or severity of adverse effects can be increased when Penicillamine is combined with Cloprednol. |
| Azacitidine | The risk or severity of adverse effects can be increased when Azacitidine is combined with Cloprednol. |
| Carboplatin | The risk or severity of adverse effects can be increased when Carboplatin is combined with Cloprednol. |
| Dactinomycin | The risk or severity of adverse effects can be increased when Dactinomycin is combined with Cloprednol. |
| Azathioprine | The risk or severity of adverse effects can be increased when Azathioprine is combined with Cloprednol. |
| Hydroxyurea | The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Cloprednol. |
| Mycophenolic acid | The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Cloprednol. |
| Topotecan | The risk or severity of adverse effects can be increased when Topotecan is combined with Cloprednol. |
| Mercaptopurine | The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Cloprednol. |
| Thalidomide | The risk or severity of adverse effects can be increased when Thalidomide is combined with Cloprednol. |
| Melphalan | The risk or severity of adverse effects can be increased when Melphalan is combined with Cloprednol. |
| Fludarabine | The risk or severity of adverse effects can be increased when Fludarabine is combined with Cloprednol. |
| Flucytosine | The risk or severity of adverse effects can be increased when Flucytosine is combined with Cloprednol. |
| Capecitabine | The risk or severity of adverse effects can be increased when Capecitabine is combined with Cloprednol. |
| Procarbazine | The risk or severity of adverse effects can be increased when Procarbazine is combined with Cloprednol. |
| Arsenic trioxide | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Cloprednol. |
| Idarubicin | The risk or severity of adverse effects can be increased when Idarubicin is combined with Cloprednol. |
| Estramustine | The risk or severity of adverse effects can be increased when Estramustine is combined with Cloprednol. |
| Mitoxantrone | The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Cloprednol. |
| Lomustine | The risk or severity of adverse effects can be increased when Lomustine is combined with Cloprednol. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Cloprednol. |
| Decitabine | The risk or severity of adverse effects can be increased when Decitabine is combined with Cloprednol. |
| Nelarabine | The risk or severity of adverse effects can be increased when Nelarabine is combined with Cloprednol. |
| Abatacept | The risk or severity of adverse effects can be increased when Abatacept is combined with Cloprednol. |
| Stepronin | The risk or severity of adverse effects can be increased when Stepronin is combined with Cloprednol. |
| Hydroxychloroquine | The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Cloprednol. |
| Castanospermine | The risk or severity of adverse effects can be increased when Castanospermine is combined with Cloprednol. |
| Vorinostat | The risk or severity of adverse effects can be increased when Vorinostat is combined with Cloprednol. |
| 2-Methoxyethanol | The risk or severity of adverse effects can be increased when 2-Methoxyethanol is combined with Cloprednol. |
| Brequinar | The risk or severity of adverse effects can be increased when Brequinar is combined with Cloprednol. |
| Pirfenidone | The risk or severity of adverse effects can be increased when Pirfenidone is combined with Cloprednol. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Cloprednol. |
| Interferon alfa | The risk or severity of adverse effects can be increased when Interferon alfa is combined with Cloprednol. |
| Glatiramer | The risk or severity of adverse effects can be increased when Glatiramer is combined with Cloprednol. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Cloprednol. |
| Human interferon omega-1 | The risk or severity of adverse effects can be increased when Human interferon omega-1 is combined with Cloprednol. |
| Apremilast | The risk or severity of adverse effects can be increased when Apremilast is combined with Cloprednol. |
| Canakinumab | The risk or severity of adverse effects can be increased when Canakinumab is combined with Cloprednol. |
| Tocilizumab | The risk or severity of adverse effects can be increased when Tocilizumab is combined with Cloprednol. |
| Rilonacept | The risk or severity of adverse effects can be increased when Rilonacept is combined with Cloprednol. |
| Mepolizumab | The risk or severity of adverse effects can be increased when Mepolizumab is combined with Cloprednol. |
| Abetimus | The risk or severity of adverse effects can be increased when Abetimus is combined with Cloprednol. |
| Golimumab | The risk or severity of adverse effects can be increased when Golimumab is combined with Cloprednol. |